A clinical trial of avapritinib versus regorafenib (Stivarga®) for people with advanced GIST that has progressed following first-line treatment with imatinib (Gleevec®) and one or two additional treatment regimens (third-line or fourth-line GIST).
Peking University Cancer Hospital (Beijing Cancer Hospital, Peking University School of Clinical Oncology, and Beijing Institute of Oncology) was founded in 1976. It is a Class III oncology specialist hospital co-managed by Peking University and Beijing Hospital Administration. Peking University Cancer Hospital has 34 clinical departments, 14 medical technology departments, 17 basic research departments, and 776 open beds.
Beijing, China Clinical Trial Location
Beijing Cancer Hospital
52 Fucheng Rd, Wu Ke Song, Haidian District,